✦ LIBER ✦

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

✍ Scribed by Francis J. Giles; Eric J. Feldman; Gail J. Roboz; Richard A. Larson; Steven W. Mamus; Jorge E. Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M. O’Brien; Hagop M. Kantarjian

Book ID: 108403292
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 72 KB
Volume: 27
Category: Article
ISSN: 0145-2126
DOI: 10.1016/s0145-2126(03)00094-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of low-dose decitabine in

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

✍ Yasuhiro Oki; Hagop M. Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'Brien 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views